Trevena, Inc.(TRVN) was a big mover last session, as the company saw its shares rise roughly 52% on the day. The upside came on the company's announcement of positive results on Phase 2b trial of its postoperative pain medication - TRV130 - after the markets closed on Monday. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $5.60-$6.80 in the past one-month time frame.
In the last 30 days, the company has seen three upward and one downward estimate revisions, while the Zacks Consensus Estimate moved higher, suggesting that more solid trading could be ahead for Trevena. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Trevena currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
A better-ranked biomedical/gene stock is Gilead Sciences Inc. (GILD) with a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report